Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 12.86
CVM's Cash to Debt is ranked higher than
70% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CVM: 12.86 )
CVM' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 12.86

Equity to Asset 0.60
CVM's Equity to Asset is ranked higher than
69% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CVM: 0.60 )
CVM' s 10-Year Equity to Asset Range
Min: -0.51   Max: 0.99
Current: 0.6

-0.51
0.99
F-Score: 4
Z-Score: -12.00
M-Score: -3.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -11437.44
CVM's Operating margin (%) is ranked higher than
51% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. CVM: -11437.44 )
CVM' s 10-Year Operating margin (%) Range
Min: -190240   Max: -928.57
Current: -11437.44

-190240
-928.57
Net-margin (%) -10352.61
CVM's Net-margin (%) is ranked higher than
51% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. CVM: -10352.61 )
CVM' s 10-Year Net-margin (%) Range
Min: -154060   Max: 6851.63
Current: -10352.61

-154060
6851.63
ROE (%) -210.02
CVM's ROE (%) is ranked higher than
53% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. CVM: -210.02 )
CVM' s 10-Year ROE (%) Range
Min: -1352.47   Max: 57.13
Current: -210.02

-1352.47
57.13
ROA (%) -112.18
CVM's ROA (%) is ranked higher than
53% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. CVM: -112.18 )
CVM' s 10-Year ROA (%) Range
Min: -238.89   Max: 25.01
Current: -112.18

-238.89
25.01
ROC (Joel Greenblatt) (%) -2991.20
CVM's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. CVM: -2991.20 )
CVM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5737.42   Max: -172.63
Current: -2991.2

-5737.42
-172.63
» CVM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CVM Guru Trades in

CVM Guru Trades in

Q4 2013

CVM Guru Trades in Q4 2013

Jim Simons 61,700 sh (New)
» More
Q1 2014

CVM Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CVM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.83
CVM's P/B is ranked higher than
87% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. CVM: 2.83 )
CVM' s 10-Year P/B Range
Min: 1.63   Max: 53.55
Current: 2.83

1.63
53.55
P/S 153.57
CVM's P/S is ranked higher than
58% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. CVM: 153.57 )
CVM' s 10-Year P/S Range
Min: 57   Max: 1660
Current: 153.57

57
1660
EV-to-EBIT -1.61
CVM's EV-to-EBIT is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CVM: -1.61 )
CVM' s 10-Year EV-to-EBIT Range
Min: -29.8   Max: -0.5
Current: -1.61

-29.8
-0.5
Current Ratio 5.22
CVM's Current Ratio is ranked higher than
75% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. CVM: 5.22 )
CVM' s 10-Year Current Ratio Range
Min: 0.17   Max: 160
Current: 5.22

0.17
160
Quick Ratio 4.79
CVM's Quick Ratio is ranked higher than
75% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CVM: 4.79 )
CVM' s 10-Year Quick Ratio Range
Min: 0.04   Max: 160
Current: 4.79

0.04
160

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.29
CVM's Price/Net Cash is ranked higher than
85% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. CVM: 9.29 )
CVM' s 10-Year Price/Net Cash Range
Min: 2.75   Max: 930
Current: 9.29

2.75
930
Price/Net Current Asset Value 8.13
CVM's Price/Net Current Asset Value is ranked higher than
84% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. CVM: 8.13 )
CVM' s 10-Year Price/Net Current Asset Value Range
Min: 2.74   Max: 465
Current: 8.13

2.74
465
Price/Tangible Book 2.95
CVM's Price/Tangible Book is ranked higher than
90% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. CVM: 2.95 )
CVM' s 10-Year Price/Tangible Book Range
Min: 1.87   Max: 52.5
Current: 2.95

1.87
52.5
Earnings Yield (Greenblatt) -62.10
CVM's Earnings Yield (Greenblatt) is ranked lower than
51% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CVM: -62.10 )
CVM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -62.1

Analyst Estimate

Sep14 Sep15
Revenue(Mil) 0 0
EPS($) -0.43 -0.35
EPS without NRI($) -0.43 -0.35

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LSRN.Germany,
CEL-SCI Corp was incorporated on March 22, 1983, in the state of Colorado. The Company is engaged in the research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. The Company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
» More Articles for CVM

Headlines

Articles On GuruFocus.com
Coverage Initiation Report Focuses on CEL-SCI Corporation Oct 15 2014 
CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 
CELSCISci Corp Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
NEW STORY CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with... Dec 08 2014
CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7... Dec 08 2014
NEW STORY CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases... Dec 02 2014
CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight... Dec 02 2014
NEW STORY CEL-SCI Enrolls 22 Patients during October in Its Phase III Immunotherapy Head and Neck... Nov 03 2014
CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial Nov 03 2014
NEW STORY CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million Nov 02 2014
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million Oct 24 2014
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Oct 23 2014
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Oct 22 2014
NEW STORY CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants Oct 21 2014
NEW STORY CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering Oct 21 2014
CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering Oct 21 2014
CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants Oct 21 2014
NEW STORY CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants Oct 20 2014
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants Oct 20 2014
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial Oct 03 2014
Coverage Initiation Report Focuses on CEL-SCI Corporation Oct 01 2014
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for... Sep 29 2014
University of Minnesota Masonic Cancer Center Joins CEL-SCI’s Phase III Head & Neck Cancer Trial Sep 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK